This white paper from Abbott examines a cross-section of the global healthcare system leveraging primary research with 1,400+ respondents including patients, physicians, and administrators.
The Covid-19 pandemic has forced healthcare systems and physician’s practices to innovate and try new approaches to care delivery, resulting in the explosive growth of telehealth services. But a comprehensive digital solution can involve much more than the video encounters people typically associate with virtual care.
The COVID-19 pandemic has put a spotlight on the need for effective tools for quality measurement and reporting initiatives. Both Medicare and Medicaid are being impacted by changes to the way care is delivered and data is captured.
After attending several virtual scientific conferences since the start of the COVID-19 lockdown, TBWA\WorldHealth explores which practices should stay, which ones will need to come back, and how pharmaceutical brands can stand out in this medium.
The Consistent Testing Terminology Working Group published a white paper with industry-wide recommendations for precision medicine testing terms to be utilized in patient education and communication.
COVID-19 has changed nearly every aspect of healthcare as we know it. Pharmaceutical commercial organizations must quickly adapt to the present while simultaneously planning for a dramatically different future.
This white paper considers how incorporating more virtual/hybrid trials and decentralized research into clinical development can better integrate healthcare into patients’ real lives and accelerate approval of new medications.
This guide explores the different sources of funding available to biotech startups and their relative merits, and how you should best utilize that funding at each stage of your research.
Imagine a financial ecosystem that interconnects payers and providers. It’s essential to the financial well-being of any provider organization, but the current claims and payment system is inefficient and outdated. Transparency, technology and trust are 3 critical elements to evolve the payer-provider relationship for fewer denials, patient payment estimations, reduced administrative costs and more.
Powered by Xconomy, November 2019’s What’s Next in Neuroscience Therapies event brought together scientists, entrepreneurs and biotech executives at the Hyatt Regency San Francisco to discuss their work developing next-generation neuroscience therapies and technologies in areas such as spinal-cord injuries, precision mental health, dementia and Alzheimer’s disease.
